A carregar...
Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Targeted therapy for metastatic renal cell carcinoma (mRCC) was introduced a decade ago and since then, a number of therapeutic options have been developed. Vascular endothelial growth factor-targeted therapy is the widely accepted first-line option for mRCC. After progression, treatment in the seco...
Na minha lista:
| Publicado no: | Can Urol Assoc J |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Canadian Medical Association
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215301/ https://ncbi.nlm.nih.gov/pubmed/28096936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.4292 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|